Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 29-day, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
Brief Summary: GSK1278863 is an orally available, hypoxia-inducible factor - prolyl hydroxylase inhibitor, currently being investigated as a treatment for anemia associated with chronic kidney disease. GSK1278863 has been given as a once daily regimen in clinical studies to date. However, physicians in countries that use a three-times weekly hemodialysis schedule prefer to give the anemia medicine at the same time as the dialysis session. This study will test how well GSK1278863 can maintain hemoglobin levels when given three-times weekly, for 29 days.

This study will describe the relationship between hemoglobin and GSK1278863 given three-times weekly. The data from this study will allow for conversion of once daily doses to three-times weekly doses.


Options:
A: Arm Label: Roxadustat; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Epoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Epoetin Alfa | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Roxadustat
B: Arm Label: Dose 1 JTZ-951 or Placebo; Type: EXPERIMENTAL; Interventions: Drug: JTZ-951, Drug: Placebo | Arm Label: Dose 2 JTZ-951 or Placebo; Type: EXPERIMENTAL; Interventions: Drug: JTZ-951, Drug: Placebo | Arm Label: Dose 3 JTZ-951 or Placebo; Type: EXPERIMENTAL; Interventions: Drug: JTZ-951, Drug: Placebo | Arm Label: Dose 4 JTZ-951 or Placebo; Type: EXPERIMENTAL; Interventions: Drug: JTZ-951, Drug: Placebo | Intervention Type: DRUG; Name: JTZ-951; Assigned to Arm(s): Dose 1 JTZ-951 or Placebo, Dose 2 JTZ-951 or Placebo, Dose 3 JTZ-951 or Placebo, Dose 4 JTZ-951 or Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Dose 1 JTZ-951 or Placebo, Dose 2 JTZ-951 or Placebo, Dose 3 JTZ-951 or Placebo, Dose 4 JTZ-951 or Placebo
C: Arm Label: Part 1: ESA-Naïve Participants - Low Weight Based Dosing; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Part 1: ESA-Naïve Participants - Standard Weight Based Dosing; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Part 1: ESA-Treated Participants - Low Weight Based Dosing; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Part 1: ESA-Treated Participants - Standard Weight Based Dosing; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Part 2: Roxadustat QW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Part 2: Roxadustat BIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Part 2: Roxadustat TIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Part 1: ESA-Naïve Participants - Low Weight Based Dosing, Part 1: ESA-Naïve Participants - Standard Weight Based Dosing, Part 1: ESA-Treated Participants - Low Weight Based Dosing, Part 1: ESA-Treated Participants - Standard Weight Based Dosing, Part 2: Roxadustat BIW, Part 2: Roxadustat QW, Part 2: Roxadustat TIW
D: Arm Label: GSK1278863 10 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 15 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 25 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: GSK1278863 30 mg; Type: EXPERIMENTAL; Interventions: Drug: GSK1278863 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: GSK1278863 matching Placebo | Intervention Type: DRUG; Name: GSK1278863; Assigned to Arm(s): GSK1278863 10 mg, GSK1278863 15 mg, GSK1278863 25 mg, GSK1278863 30 mg | Intervention Type: DRUG; Name: GSK1278863 matching Placebo; Assigned to Arm(s): Placebo

Answer: D